Biogen (BIIB) News
NASDAQ: BIIBHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
225.71+7.28 (+3.33%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
BIIB news summary
We found 2 recent headlines mentioning Biogen (BIIB): 0 in the past week and 1 in the past 30 days, most often from Nasdaq. For price context, BIIB is up 3.33% at $225.71. The most recent story, "Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead", was published by Nasdaq on Sep 18, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Biogen headlines
- Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead(RTTNews) - Biotech investors tracked a busy week marked by regulatory approvals, strategic collaborations, workforce restructuring and key clinical trial readouts.NasdaqAEMD, AZN, BBNX, BIIB
- Weekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG Deals(RTTNews) - This week's biotech roundup saw a flurry of FDA and EU approvals across neurology, oncology, cardiology, and rare diseases, alongside new partnerships, trial readouts, and restructuring…NasdaqAPVO, ASND, AZN, BIIB